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Abstract  
 
One of the efforts to cure breast cancer is a combination of the chemotherapeutic agent 
with medicinal plants. This study was conducted to examine the activity of the combination 
between doxorubicin, curcuma rhizome (Curcuma xanthorriza Roxb.) ethanolic extract (CEE), and 
awar-awar leaves (Ficus septica Burm.f.) ethanolic extract (AAE) in inducing apoptosis and 
modulating the cell cycle progression in breast cancer T47D cells. The combination activity was 
performed using three series of concentration, 1/3; 1/6 and 1/12 of IC50, The combination index 
(CI) of doxorubicin, CEE and AEE was determined under MTT assay. The result showed that the 
combination of 10 µM, 5 µg/mL, 1 µg/mL concentrations of  doxorubicin, CEE and AEE 
respectively result in synergistic effect with CI values less than 1. The treatment exhibited the 
cell accumulation in S phase (27.7%) against T47D breast cancer cells confirmed through cell 
cycle examination by flow cytometry. These results provided the evidence that CEE and the AEE 
can be developed as co-chemotherapeutic agents combined with doxorubicin to improve the 
effectiveness of breast cancer treatment. 
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INTRODUCTION 
 
A chemotherapeutic agent, like doxorubicin, 
is used for the breast cancer treatment frequently. 
However, the main problems that arise in the use of 
doxorubicin chemotherapeutic agents in the 
treatment of breast cancer are the emergence of side 
effects and resistance. The side effects of 
doxorubicin resulted in suppression of the immune 
system (Wattanapitayaku, et al., 2004) and 
resistance (Mechetner, et al., 1998). The use of co-
agents in combination with chemotherapeutic agents 
is an attempt to improve the effectiveness of cancer 
therapy agents while lowering the side effects of 
chemotherapy agent (Sharma, et al.,  2004). 
Curcuma rhizome (Curcuma Roxb xanthorriza) and 
Awar-awar leaves (Ficus septica Burm.f.) are two of 
medicinal plants in Indonesia that used regularly for 
herbal therapy in breast cancer. Curcuma contains 
curcumin which is known to have anticancer activity 
with the mechanism of action of the anti-
proliferation and antiangiogenesis. In addition, 
curcumin is able to inhibit the activation of NF-κB 
(Foo and Nolan, 1999). Meanwhile, Awar-awar 
contains phenanthroindolizidine, an alkaloid that 
were known to have cytotoxic activity on cells HCT-
8, NUGC, Hone-1 (Damu, et al., 2005). Previous 
study showed that ethanolic extract of awar-awar 
leaves (EFS) exhibits cytotoxic activity suspected to 
induce apoptosis through suppression of protein 
expression antiapoptosis in MCF-7 cells (Sekti, et al., 
2010). Moreover, Haryanti et al. also reported that 
AEE incombination with Sappan woods ethanolic 
extract increase the potensi of doxorubicin to induce 
apoptosis in MCF-7 cells (Haryanti, et al., 2016). 
Based on the study above, ethanolic extract of 
awar-awar (AEE) and ethanolic extract of curcuma 
(CEE) are potential to be developed as an co-
chemotherapy agent in breast cancer treatment.  
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The combination of ethanolic extract of awar-awar 
and ethanolic extract of curcuma with doxorubicin 
are expected to reduce the dose and side effects of  
doxorubicin and breast cancer cell resistance due to 
the use of doxorubicin. This study is conducted to 
determine the synergistic effect of cytotoxic effect 
brought about by a combination of doxorubicin, 
ethanolic extract of curcuma (CEE) and ethanolic 
extract of awar-awar (AEE) through the induction of 
apoptosis and cell cycle modulation of T47D breast 
cancer cells. 
 
MATERIAL AND METHOD 
 
Compounds and cell culture  
The samples were resulted from extraction 
using ethanol 70% where the dried powder of 
Curcuma and Awar-awar leaves were obtained from 
Balai Besar Pusat Penelitian Tanaman Obat dan 
Obat Tradisional (B2P2TOOT), Tawangmangu, 
Indonesia.  While T47D cells were gifted from Prof. 
Masashi Kawaichi, Laboratorium of Gene Function 
in Animal, Graduate School of Biological Science, 
Nara Institute of Science and Technology (NAIST), 
Japan, and were grown in Dulbecco’s Modified 
Eagle Media (DMEM) high glucose (Gibco), 
supplemented with 10% Fetal Bovine Serum (FBS 
Qualified, Gibco, Invitrogen USA), 1.5% (w/w) 
penisilin-streptomisin (Gibco, Invitrogen USA), and 
0.5 % fungizone (Gibco, Invitrogen USA). Cells 
were incubated at 37°C and 5% CO2.   
 
MTT assay  
T47D cells/well were grown in 96-well plate 
(1x104 /well) before being exposured to samples 
treatment. For cell viability assay, cells were treated 
for 24 hours with increasing concentration of single 
treatment of CEE and AEE and in combination with 
doxorubicin. As negative control, only growth 
medium was added. At 100 µg/mL of MTT solution 
(0.5 mg/ml in PBS) was added to each well 
continued with incubation for 3 hours at 37°C. The 
reaction was stopped by dilution with 10% (w/v) 
Sodium Dodecyl Sulphate 10% in 0.01 N HCl, and 
cells were incubated overnight. The absorbance was 
determined by using ELISA reader at λ 595 nm.  
 
 
 
Flowcytometry  
FACS analysis was carried out to investigate 
apoptosis quantification and cell cycle distribution. 
T47D cells (5x105/well) were grown in 6-well plate 
and treated with CEE, AEE, doxorubicin (WAKO) 
and combination of them. Trypsinized adherent cells 
were collected and were prepared for detection. Cell 
apoptosis was detected by using a FITC-Annexin V 
Apoptosis Detection Kit (Biovision, USA). For cell 
cycle analysis, the trypsinized adherent cells were 
collected and detected by adding flow cytometry 
reagents [(25µL propidium iodide (minimum 95% 
(HPLC), Sigma-Aldrich Co., St. Louis, MO, 63178, 
USA), 2.5µL RNase, 0.5µl Triton-X (triton X-100 
for GC, E.Merck, 64271, Darmstadt, Germany) in 
500µL PBS)], followed by incubation at room 
temperature for 10 minutes. The cell suspension was 
transferred into a flow cytometer tube and its cell 
cycle profile was read by using flow cytometer 
FACS-Calibur. The cell cycle profile was analyzed 
by Flowing software. 
 
RESULTS 
 
Cytotoxic combination effects of Doxorubicin, 
AEE and CEE in T47D Cell 
IC50 values obtained from the AEE and CEE 
respectively are 6.7 ± 0.65 µg/mL and 29.3 ± 1.76 
µg/mL. The IC50 value of the treatments showed that 
the AEE and CEE as a potent cytotoxic agent 
because the value earned is less than 100 µg/mL 
(Ueda, et al., 2002). Meanwhile, doxorubicin has 
IC50 value of 60 µM. Cytotoxic test of combination 
treatment was carried out at a concentration of 1/12, 
1/3, and 1/6 IC50 of each samples. 
The combination of doxorubicin-CEE-AEE 
showed morphological changes and decrease in 
density of the cells after the combination happened 
(Fig. 1). The combination of the 1/6 IC50 CEE 
concentration (5 µg/mL), AEE (1 µg/mL), and 10 
µM doxorubicin can lower the viability of T47D 
cells of 55.77% (Fig. 2b) with CI values of 0.63 (CI 
<1) (Table 1) shows a synergistic effect among the 
three test compounds. These results indicate 
ethanolic extract of curcuma and awar-awar can be 
used as an agent to be combined with doxorubicin in 
T47D cells.    
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Figure 1. The effect of combination treatment of  AEE-CEE-doxorubicin against T47D cell growth. About 8,000 
cells / wells in 96-well plates were incubated for 24 hours in Hi-glucose DMEM media without or with treatment. 
Observations were made under inverted microscope (a) Cells control; (B) Combination of AEE-CEE-Doxorubicin 
1/12 IC50; (C) The combination of doxorubicin AEE-CEE- IC50 1/6; (D) A combination of doxorubicin 1/3 CEE- AEE-
IC50. Morphology of living T47D cell is shown by the image (        ) and cells undergoing morphological changes is 
indicated by the arrow breaking (         ). CI values combination of AEE-CEE-Doxorubicin show a synergistic effect 
(CI <1). 
 
 
Table 1. Combination Index (CI) Value of  doxorubicin combination with the AEE, and CEE on T47D cells 
 
Rasio Konsentrasi % Viabilitas AEE-CEE-
Doxorubicin 
CI 
1/12  IC50 60.67 0,74 
1/6  IC50 44.23 0,63 
1/3  IC50 41.02 1,04 
	
	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
Figure 2.  Combination relationship graph of AEE-CEE and doxorubicin against T47D cell viability. Combination 
of the AEE-CEE-Doxorubicin. About 8,000 cells / wells were given a combination treatment and were incubated 
for 24 hours. Observed changed in viability T47D cell and combination index analysis. Combination treatment 
shows viability loss of optimum  Doxorubicin with synergistic effect. * Significant differences (p<0.05). 
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Combination of AEE-CEE-doxorubicin 
modulate cell cycle progression in T47D 
breast cancer cells 
The result showed that the AEE causes an 
accumulation in S phase, while in the CEE the 
accumulation occurs in S phase and G2/M (Fig. 3). 
The combination of CEE, AEE with doxorubicin 
leads to accumulation of the cell cycle in the S phase 
by 31.24% compared to single doxorubicin treatment 
causes cells to accumulate in G2/M phase (Fig. 3). 
The percentage of cell accumulation combination 
due to the combination treatment in S phase is 
increased   to  21.34%   compared   to  9.90%  single  
 
 
doxorubicin. Cell accumulation is possible because 
of a cell cycle arrest in the phase.  
 
Combination of AEE-CEE-doxorubicin induce 
cell apoptosis 
The value of cell death in sequence on a 
single doxorubicin and its combination with 
ethanolic extract of curcuma and awar-awar is 
5.79% and 9.5%. The results shows that the 
ethanolic extract of curcuma and awar-awar affect 
the sensitivity of the T47D cells as a result of 
treatment of doxorubicin, but have not been able to 
induce apoptosis of T47D breast cancer cells 
significantly (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Detection of cell cycle distribution using flow cytometry. T47D cells (5x105) were grown in 6 well plates and 
were incubated for 24 hours in high glucose DMEM media without or with treatment. Flow cytometry detection 
using PI reagent against T47D cells after AEE treatment 1μg / ml, CEE 5μg / ml, Dox 10nM and a combination of all 
those three. Combination of AEE-CEE-Doxorubicin. Flow cytometry Analysis using flowing  
 
 
 
 
 
 
 
 
 
 
 
 
Cell control 
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Figure 4. Effect of CEE, AEE, Doxorubicin treatment and AEE-CEE-doxorubicin against cell death. About 5x105 
cells grown in 6-well plates and were incubated for 24 hours in high glucose DMEM media with or without 
treatment. Flowcytometry detection of cell death using V-FITC / PI annexin against T47D breast cancer cells after 
treatment using 5μg / ml CEE, 1 ug / ml AEE, 10 nM doxorubicin, and a combination of all those three . R1 quadrant 
shows a living cell, R2: early apoptosis, R3: late apoptosis, R4: necrosis. (a) Cells control; (B) Combination of AEE-
CEE-Doxorubicin 1/12 IC50; (C) The combination of doxorubicin AEE-CEE- IC50 1/6; (D) A combination of 
doxorubicin 1/3 CEE- AEE-IC50. 
 
DISCUSSION 
 
Single treatment analysis of AEE in breast 
cancer T47D cells causes an accumulation of cells in 
S phase (23.38%). It is caused due to the up-
regulation of CDK inhibitor p21 (Nugroh, et al.,  
2013). The CEE treatment causes the cells to 
accumulate in G2/M phase (22.10%) and the S phase 
(15.03%). This is consistent with previous studies 
that curcumin against Colo 205 cells also cause 
G2/M arrest, and this is due to the down-regulation 
of Cdc24c, Cdk1, and Cyclin B (Su, et al., 2006). 
The xanthorizol contained in CEE against colon 
cancer cells HCT 116 also can lead to S arrest and 
G2/M arrest (Kang, et al., 2009). In addition, the 
analysis of the cell cycle at doxorubicin single 
treatment against T47D breast cancer cells causes an 
accumulation of cells in G2/M phase (24.30%). This 
corresponds to previous research regarding cell cycle 
analysis. Single treatment of doxorubicin 
chemotherapeutic agent causes the cells to 
accumulate in G2/M phase in T47D cells. The 
accumulation of cells in G2/M phase as a result of 
treatment of doxorubicin causes DNA damage thus 
affecting the ATM-ATR signaling. This will activate 
the protein kinase Chk1 and Chk2, inhibiting 
Cdc2/Cyclin B, causing G2/M arrest (Kolb, et al., 
2012). 
The combination treatment of the AEE-CEE-
Doxorubicin can change cell accumulation of G2/M 
phase to the S phase of doxorubicin treatment. So 
the inhibition process occurs during the synthesis 
process of genetic material. In the S phase, cyclin A 
binds to Cdk2 that activate cells to the G2 phase. 
This activation is inhibited by p27, p21, and p57 
(Shah and Schwartz, 2001). So the combination 
treatment of CEE, AEE, and doxorubicin could 
potentially cause up-regulation of p21 that can 
inhibit cyclin a complex binds to Cdk2. Moreover, 
the possibility can also be caused due to the down-
regulation of cyclin A, which plays a role in S phase, 
causing S phase arrest.  
Study focusing on the molecular pathways 
involved by Nugroho, 2013 showed that the 
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ethanolic hexane insoluble fraction (HIF) of awar-
awar leaves were able to induce apoptosis through 
p53 pathway emphasis on independent, i.e. through 
the suppression of Bcl-2 expression. In addition, the 
combination of HIF and doxorubicin could induce 
apoptosis by increasing the expression of cleavage-
PARP cutting through PARP (Nugroho, et al., 2013). 
Curcumin was able to suppress levels of NF-kappaB 
due to the activation of TNF-alpha, which was one 
of apoptosis signaling pathways, so that the effect of 
curcumin on inhibiting NF-κВ could stimulate 
apoptosis and suppresses proliferation (Aggarwal, et 
al., 2006). However, the combination of CEE, AEE, 
and doxorubicin has not been able to lead to the 
induction of apoptosis of the breast cancer T47D 
cells. This is possibly due to the reaction between 
compounds in the extract content that has not been 
able to increase apoptosis induction. The mechanism 
of cytotoxic compounds contained in the AEE and 
CEE is possible through p53-dependent pathway.  
Curcuma genus has been reported to inhibit 
proliferation of T47D breast cancer cells (Widowati, 
et al., 2011). Current results improve the existing 
scientific evidence about the activities of ethanolic 
extract of curcuma and awar-awar against T47D 
breast cancer cells in combination with doxorubicin. 
However, the study also required further research to 
determine the proteins involved in knowing the 
molecular mechanisms that mediate synergism in 
combination of ethanolic extract of awar-awar and 
curcuma, such as protein expression of p53, Bcl-2 
and NF-κB by in vitro on breast cancer T47D cells.  
 
CONCLUSION 
 
The conclusion of this research is that awar-
awar extract and curcuma extract has potential to 
increase the sensitivity of doxorubicin against T47D 
breast cancer cells by in vitro. The combination of 
AEE, CEE and doxorubicin has a synergistic effect 
in giving cytotoxic effects on breast cancer cells by 
mechanisms of cell cycle modulation. of NF-kB by 
in vitro on breast cancer cells T47D. 
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